BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 34666554)

  • 1. A narrative synthesis of research with 5-MeO-DMT.
    Ermakova AO; Dunbar F; Rucker J; Johnson MW
    J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
    Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
    J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
    Halberstadt AL
    Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
    Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
    Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
    Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
    Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT
    Riga MS; Lladó-Pelfort L; Artigas F; Celada P
    Neuropharmacology; 2018 Nov; 142():219-230. PubMed ID: 29221792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
    Shen HW; Jiang XL; Winter JC; Yu AM
    Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
    Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
    Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.
    Uthaug MV; Lancelotta R; van Oorsouw K; Kuypers KPC; Mason N; Rak J; Šuláková A; Jurok R; Maryška M; Kuchař M; Páleníček T; Riba J; Ramaekers JG
    Psychopharmacology (Berl); 2019 Sep; 236(9):2653-2666. PubMed ID: 30982127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
    Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
    J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
    Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
    Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
    Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
    Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
    Riga MS; Soria G; Tudela R; Artigas F; Celada P
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
    Halberstadt AL; Koedood L; Powell SB; Geyer MA
    J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.
    Reckweg J; Mason NL; van Leeuwen C; Toennes SW; Terwey TH; Ramaekers JG
    Front Pharmacol; 2021; 12():760671. PubMed ID: 34912222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.
    Lancelotta RL; Davis AK
    J Psychoactive Drugs; 2020; 52(3):273-281. PubMed ID: 32148190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice.
    Jefferson SJ; Gregg I; Dibbs M; Liao C; Wu H; Davoudian PA; Woodburn SC; Wehrle PH; Sprouse JS; Sherwood AM; Kaye AP; Pittenger C; Kwan AC
    Neuropsychopharmacology; 2023 Aug; 48(9):1257-1266. PubMed ID: 37015972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative and Quantitative Analysis of Tryptamines in the Poison of Incilius alvarius (Amphibia: Bufonidae).
    Schwelm HM; Zimmermann N; Scholl T; Penner J; Autret A; Auwärter V; Neukamm MA
    J Anal Toxicol; 2022 May; 46(5):540-548. PubMed ID: 33851996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.
    Halberstadt AL; Nichols DE; Geyer MA
    Psychopharmacology (Berl); 2012 Jun; 221(4):709-18. PubMed ID: 22222861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
    Jiang XL; Shen HW; Yu AM
    Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.